Variola virus F1L is a Bcl-2-like protein that unlike its vaccinia virus counterpart inhibits apoptosis independent of Bim

Subversion of host cell apoptosis is an important survival strategy for viruses to ensure their own proliferation and survival. Certain viruses express proteins homologous in sequence, structure and function to mammalian pro-survival B-cell lymphoma 2 (Bcl-2) proteins, which prevent rapid clearance of infected host cells. In vaccinia virus (VV), the virulence factor F1L was shown to be a potent inhibitor of apoptosis that functions primarily be engaging pro-apoptotic Bim. Variola virus (VAR), the causative agent of smallpox, harbors a homolog of F1L of unknown function. We show that VAR F1L is a potent inhibitor of apoptosis, and unlike all other characterized anti-apoptotic Bcl-2 family members lacks affinity for the Bim Bcl-2 homology 3 (BH3) domain. Instead, VAR F1L engages Bid BH3 as well as Bak and Bax BH3 domains. Unlike its VV homolog, variola F1L only protects against Bax-mediated apoptosis in cellular assays. Crystal structures of variola F1L bound to Bid and Bak BH3 domains reveal that variola F1L forms a domain-swapped Bcl-2 fold, which accommodates Bid and Bak BH3 in the canonical Bcl-2-binding groove, in a manner similar to VV F1L. Despite the observed conservation of structure and sequence, variola F1L inhibits apoptosis using a startlingly different mechanism compared with its VV counterpart. Our results suggest that unlike during VV infection, Bim neutralization may not be required during VAR infection. As molecular determinants for the human-specific tropism of VAR remain essentially unknown, identification of a different mechanism of action and utilization of host factors used by a VAR virulence factor compared with its VV homolog suggest that studying VAR directly may be essential to understand its unique tropism.

[1]  Johnm . Taylor,et al.  The Vaccinia Virus Protein F1L Interacts with Bim and Inhibits Activation of the Pro-apoptotic Protein Bax* , 2006, Journal of Biological Chemistry.

[2]  A. Meyers,et al.  Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Andrews,et al.  Regulating cell death at, on, and in membranes. , 2014, Biochimica et biophysica acta.

[4]  G. McFadden,et al.  Myxoma virus M11L ORF encodes a protein for which cell surface localization is critical in manifestation of viral virulence. , 1992, Virology.

[5]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .

[6]  M. Hinds,et al.  Structural biology of the Bcl-2 family and its mimicry by viral proteins , 2013, Cell Death and Disease.

[7]  A. Fauci,et al.  Host-based antipoxvirus therapeutic strategies: turning the tables. , 2005, Journal of Clinical Investigation.

[8]  D. Stuart,et al.  Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein , 2007, The Journal of general virology.

[9]  D. Tscharke,et al.  The vaccinia virus N1L protein is an intracellular homodimer that promotes virulence. , 2002, The Journal of general virology.

[10]  Piotr Sliz,et al.  Collaboration gets the most out of software , 2013, eLife.

[11]  T. Kuwana,et al.  BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak* , 2010, The Journal of Biological Chemistry.

[12]  J. Berger,et al.  Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl‐2 , 2007, Protein science : a publication of the Protein Society.

[13]  W. Hammerschmidt,et al.  Epstein-Barr Virus Provides a New Paradigm: A Requirement for the Immediate Inhibition of Apoptosis , 2005, PLoS biology.

[14]  G. Häcker,et al.  Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis , 2008, Cell Death and Differentiation.

[15]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[16]  F. Bushman,et al.  Structural basis for specificity in the poxvirus topoisomerase. , 2006, Molecular cell.

[17]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[18]  G. McFadden,et al.  Proteomic screening of variola virus reveals a unique NF-κB inhibitor that is highly conserved among pathogenic orthopoxviruses , 2009, Proceedings of the National Academy of Sciences.

[19]  W. D. Fairlie,et al.  Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands , 2008, Cell Death and Differentiation.

[20]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[21]  A. Strongin,et al.  Activity, Specificity, and Probe Design for the Smallpox Virus Protease K7L* , 2012, The Journal of Biological Chemistry.

[22]  M. Feinberg,et al.  Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases , 2005, Nature Medicine.

[23]  M. Bray,et al.  Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections , 2003, Antiviral research.

[24]  E. Reinherz,et al.  Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. , 2005, The Journal of clinical investigation.

[25]  P. Colman,et al.  Vaccinia Virus F1L Interacts with Bak Using Highly Divergent Bcl-2 Homology Domains and Replaces the Function of Mcl-1 , 2009, The Journal of Biological Chemistry.

[26]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[27]  M. Kvansakul,et al.  The Bcl-2 family: structures, interactions and targets for drug discovery , 2014, Apoptosis.

[28]  J. Kaiser.  Smallpox vaccine. A tame virus runs amok. , 2007, Science.

[29]  D. Green,et al.  A unified model of mammalian BCL-2 protein family interactions at the mitochondria. , 2011, Molecular cell.

[30]  L. Naesens,et al.  Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection , 2006, Nature.

[31]  L. Walensky,et al.  BH3-triggered structural reorganization drives the activation of proapoptotic BAX. , 2010, Molecular cell.

[32]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[33]  J. Thibault,et al.  Sheeppox Virus SPPV14 Encodes a Bcl-2-Like Cell Death Inhibitor That Counters a Distinct Set of Mammalian Proapoptotic Proteins , 2012, Journal of Virology.

[34]  Erinna F. Lee,et al.  A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. , 2007, Molecular cell.

[35]  R. Liddington,et al.  Vaccinia virus N1L protein resembles a B cell lymphoma‐2 (Bcl‐2) family protein , 2006, Protein science : a publication of the Protein Society.

[36]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[37]  Lin Chen,et al.  Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. , 2005, Genes & development.

[38]  T. Shenk,et al.  Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product , 1996, Journal of virology.

[39]  B. Schnierle,et al.  From actually toxic to highly specific – novel drugs against poxviruses , 2007, Virology Journal.

[40]  P. Colman,et al.  BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.

[41]  M. Bray.  Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. , 2003, Antiviral research.

[42]  L. Banadyga,et al.  The Fowlpox Virus BCL-2 Homologue, FPV039, Interacts with Activated Bax and a Discrete Subset of BH3-Only Proteins To Inhibit Apoptosis , 2009, Journal of Virology.

[43]  Erinna F. Lee,et al.  Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis , 2013, Cell.

[44]  R. Jordan,et al.  An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge , 2005, Journal of Virology.

[45]  P. Marrack,et al.  The Epstein–Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim , 2009, Proceedings of the National Academy of Sciences.

[46]  T. Okamoto,et al.  Deerpox Virus Encodes an Inhibitor of Apoptosis That Regulates Bak and Bax , 2010, Journal of Virology.

[47]  Carole R Baskin,et al.  Vaccinia virus vaccines: past, present and future. , 2009, Antiviral research.

[48]  P. Colman,et al.  Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1 , 2010, PLoS pathogens.

[49]  M. Hinds,et al.  The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist , 2012, Cell Death and Disease.

[50]  M. Hinds,et al.  The structural biology of BH3-only proteins. , 2014, Methods in enzymology.

[51]  S. Shchelkunov,et al.  Recombinant TNF-binding protein from variola virus as a novel potential TNF antagonist , 2009, Biochemistry (Moscow).

[52]  G. Poland,et al.  The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. , 2005, Vaccine.

[53]  T. Lithgow,et al.  Human Bcl-2 cannot directly inhibit the Caenorhabditis elegans Apaf-1 homologue CED-4, but can interact with EGL-1 , 2006, Journal of Cell Science.

[54]  J. Thibault,et al.  Structural Insight into BH3 Domain Binding of Vaccinia Virus Antiapoptotic F1L , 2014, Journal of Virology.

[55]  J. Tropea,et al.  Structure-assisted discovery of Variola major H1 phosphatase inhibitors. , 2007, Acta crystallographica. Section D, Biological crystallography.